Latest news with #HuxleyMedical
Malaysian Reserve
18-06-2025
- Health
- Malaysian Reserve
Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test
ATLANTA, Ga., June 17, 2025 /PRNewswire/ — Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the clinical validation study of its SANSA home sleep apnea test has been published in Frontiers in Neurology (Volume 16, 2025; doi: 10.3389/fneur.2025.1592690). The multicenter, prospective trial confirms that SANSA delivers comparable performance to in–lab polysomnography (PSG), the recognized gold standard for obstructive sleep apnea (OSA) diagnosis. The study, titled 'Polysomnography validation of SANSA to detect obstructive sleep apnea,' included 340 participants across seven U.S. clinical sites. SANSA's close agreement with PSG combined with its simple, single-point-of-contact, hands-free design positions it as an efficient and versatile solution to diagnose and monitor OSA. Study highlights include: Scale and diversity: Investigators highlighted the generalizability of the study results due to its large, diverse group of participants across seven academic and community sleep centers using different PSG protocols, exceeding that of most other home sleep testing study validations. Diagnostic accuracy: High apnea-hypopnea index (AHI) correlation with consensus PSG (91%), along with sensitivity of 88% and specificity of 87% for detecting moderate-to-severe OSA (AHI ≥ 15 events/hour) Total sleep time assessment: Correlation of R = 0.82 between SANSA and PSG-derived measures, with sleep epoch classification accuracy of 87% 'This publication represents an important milestone in the clinical validation of SANSA,' said Dr. Cathy Goldstein, MD, principal investigator on the study, professor of Neurology at the University of Michigan Sleep Disorders Center, and former chair of the American Academy of Sleep Medicine's Artificial Intelligence in Sleep Medicine Committee. 'As providers seek more efficient and scalable ways to diagnose sleep apnea, these findings reinforce that SANSA can deliver reliable, high-quality data without the complexity of traditional home sleep apnea testing devices.' The SANSA platform uses a wireless chest-worn patch to collect multi-parameter physiological data without the need for phone apps or technician setup. By simplifying testing, SANSA aims to expand access to timely diagnosis and treatment for millions of Americans with undiagnosed sleep apnea. The embedded reference electrocardiogram (ECG) within SANSA's suite of sensors also enables concurrent measurement of cardiac signals—opening new avenues for broader clinical applications. About Huxley MedicalHuxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research manuscript: Media ContactBrennan TorstrickChief Scientific OfficerHuxley
Yahoo
17-06-2025
- Health
- Yahoo
Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test
ATLANTA, Ga., June 17, 2025 /PRNewswire/ -- Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the clinical validation study of its SANSA home sleep apnea test has been published in Frontiers in Neurology (Volume 16, 2025; doi: 10.3389/fneur.2025.1592690). The multicenter, prospective trial confirms that SANSA delivers comparable performance to in–lab polysomnography (PSG), the recognized gold standard for obstructive sleep apnea (OSA) diagnosis. The study, titled "Polysomnography validation of SANSA to detect obstructive sleep apnea," included 340 participants across seven U.S. clinical sites. SANSA's close agreement with PSG combined with its simple, single-point-of-contact, hands-free design positions it as an efficient and versatile solution to diagnose and monitor OSA. Study highlights include: Scale and diversity: Investigators highlighted the generalizability of the study results due to its large, diverse group of participants across seven academic and community sleep centers using different PSG protocols, exceeding that of most other home sleep testing study validations. Diagnostic accuracy: High apnea-hypopnea index (AHI) correlation with consensus PSG (91%), along with sensitivity of 88% and specificity of 87% for detecting moderate-to-severe OSA (AHI ≥ 15 events/hour) Total sleep time assessment: Correlation of R = 0.82 between SANSA and PSG-derived measures, with sleep epoch classification accuracy of 87% "This publication represents an important milestone in the clinical validation of SANSA," said Dr. Cathy Goldstein, MD, principal investigator on the study, professor of Neurology at the University of Michigan Sleep Disorders Center, and former chair of the American Academy of Sleep Medicine's Artificial Intelligence in Sleep Medicine Committee. "As providers seek more efficient and scalable ways to diagnose sleep apnea, these findings reinforce that SANSA can deliver reliable, high-quality data without the complexity of traditional home sleep apnea testing devices." The SANSA platform uses a wireless chest-worn patch to collect multi-parameter physiological data without the need for phone apps or technician setup. By simplifying testing, SANSA aims to expand access to timely diagnosis and treatment for millions of Americans with undiagnosed sleep apnea. The embedded reference electrocardiogram (ECG) within SANSA's suite of sensors also enables concurrent measurement of cardiac signals—opening new avenues for broader clinical applications. About Huxley MedicalHuxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research manuscript: Media ContactBrennan TorstrickChief Scientific OfficerHuxley View original content to download multimedia: SOURCE Huxley Medical, Inc. Sign in to access your portfolio
Yahoo
29-04-2025
- Health
- Yahoo
Investigational data presented at Heart Rhythm Society demonstrates promising multi-sensing capabilities of SANSA home sleep apnea test
SAN DIEGO, April 29, 2025 /PRNewswire/ -- Huxley Medical unveiled promising investigational data from the company's SANSA monitoring platform at the Heart Rhythm Society meeting, held in San Diego from April 24-27. In the observational study, investigators evaluated the feasibility of SANSA to simultaneously assess sleep apnea, arrhythmia, and activity patterns. The study highlights the high burden of unrecognized sleep apnea in electrophysiology populations and the breadth of insights the SANSA multi-sensing platform is capable of generating from a single use. With continued development, researchers believe SANSA could simplify diagnostic workflows for complex patients and enhance cross-specialty collaboration between cardiology, electrophysiology, and sleep medicine. Key findings from the research: Previously unrecognized sleep apnea was detected in 67% (20/30) of electrophysiology patients being monitored for arrhythmias SANSA revealed sleep apnea during a daytime nap as well as overnight sleep, highlighting how typical overnight-only home sleep apnea testing may miss the full burden of disease and not capture valuable information about patients' circadian sleep patterns Simultaneous collection of ECG alongside oximetry, motion, and respiration provided valuable context to understand relationships between arrhythmia burden, sleep, and activity level The research team leading the study suggested that unifying the assessment of sleep-disordered breathing and cardiac arrhythmias could provide valuable insight into disease states and inform clinical management of complex patients. Rohit Mehta, MD, cardiac electrophysiologist at the Sanger Heart and Vascular Institute and Professor of Medicine at Wake Forest University School of Medicine, said, "A key unmet need in current diagnostic assessments is the ability to contextualize when disease occurs and to identify how different disease states influence one another. This is particularly true for frequently comorbid conditions like various arrhythmias and sleep apnea. A unified assessment could help tailor disease management for the patient and allow more specific and appropriate therapies to be provided. This study suggests promising potential for SANSA to help address this need and motivates continued clinical research and validation." Samuel Sears, PhD, ABPP, professor of cardiovascular sciences and psychology at East Carolina University and division chief of innovation and research for the East Carolina Heart Institute, added "Keeping patients active and understanding how their heart responds to physical activity is one of the most critical things we can do for our cardiac patients. Devices like SANSA that provide this level of information alongside standard Holter data could become the standard." Researchers also highlighted the promise of SANSA to streamline workflows and strengthen how different clinical specialties work together to provide care. Douglas Kirsch, MD, Medical Director of Sleep Medicine at Atrium Health and Clinical Professor of Neurology at Wake Forest University School of Medicine, said, "Siloed workflows create complexity for patients and hamper inter-specialty collaboration. Devices with muti-diagnostic capabilities, like SANSA, may enable faster and more efficient approaches to patients where both sleep and cardiac disorders are suspected." About Huxley Medical Huxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research abstract: "Simultaneously Monitoring Patterns of Arrhythmia, Sleep Apnea, and Activity with a Single Chest-worn Device" Media Contact: Brennan Torstrick Chief Scientific Officer Huxley Medical View original content to download multimedia: SOURCE Huxley Medical, Inc. Sign in to access your portfolio
